Annalisa Pinna focuses on Pharmacology, Parkinson's disease, Dopamine, Internal medicine and Endocrinology. Her research integrates issues of Amphetamine, Hydroxydopamine and Clinical trial in her study of Pharmacology. Annalisa Pinna focuses mostly in the field of Parkinson's disease, narrowing it down to topics relating to Receptor and, in certain cases, Neuroprotection.
Her Dopamine research is classified as research in Neuroscience. Her study in Agonist, Dopamine receptor and Adenosine A3 receptor is carried out as part of her Internal medicine studies. Her biological study spans a wide range of topics, including Nigrostriatal pathway and Adenosine.
Her main research concerns Dopamine, Internal medicine, Endocrinology, Pharmacology and Parkinson's disease. Her Dopamine research is within the category of Neuroscience. Her work on Dopamine receptor, Nucleus accumbens and SCH-23390 as part of general Endocrinology study is frequently linked to c-Fos, bridging the gap between disciplines.
In her study, SCH-58261 and Antagonist is inextricably linked to Adenosine A2A receptor, which falls within the broad field of Pharmacology. Her Parkinson's disease research integrates issues from Receptor, Clinical trial, Adenosine and Neuroprotection. Her study in the fields of Nigrostriatal pathway under the domain of Dopaminergic overlaps with other disciplines such as Transmission.
Annalisa Pinna mainly focuses on Dopamine, Pharmacology, Parkinson's disease, Neuroscience and Substantia nigra. Annalisa Pinna specializes in Dopamine, namely Dopamine receptor D1. Her Parkinson's disease research includes elements of Receptor, Adenosine A2A receptor, Adenosine receptor and Adenosine.
A large part of her Neuroscience studies is devoted to Dopaminergic. Her Substantia nigra research incorporates elements of Striatum, Neuroprotection, Ventral tegmental area and Tyrosine hydroxylase. Annalisa Pinna has begun a study into Pars compacta, looking into Endocrinology and Internal medicine.
Her primary areas of investigation include Pharmacology, Neuroprotection, Parkinson's disease, Dopamine and Substantia nigra. Her study in Pharmacology is interdisciplinary in nature, drawing from both Cannabinoid receptor antagonist and Rimonabant. The concepts of her Cannabinoid receptor antagonist study are interwoven with issues in Endocrinology and Receptor antagonist.
The study incorporates disciplines such as Adenosine A2A receptor and Pars compacta in addition to Neuroprotection. Her Dopamine study is related to the wider topic of Neuroscience. Her research in Preladenant intersects with topics in Agonist, Clinical trial and Abnormal involuntary movement.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats.
Sandro Fenu;Annalisa Pinna;Ennio Ongini;Micaela Morelli.
European Journal of Pharmacology (1997)
Blockade of A2a Adenosine Receptors Positively Modulates Turning Behaviour and c‐Fos Expression Induced by D1 Agonists in Dopamine‐denervated Rats
A. Pinna;G. Di Chiara;J. Wardas;M. Morelli.
European Journal of Neuroscience (1996)
Opposite effects of NMDA receptor blockade on dopaminergic D1- and D2-mediated behavior in the 6-hydroxydopamine model of turning: relationship with c-fos expression.
M Morelli;S Fenu;A Pinna;G Di Chiara.
Journal of Pharmacology and Experimental Therapeutics (1992)
Adenosine A2A Receptor Antagonists in Parkinson's Disease: Progress in Clinical Trials From the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued
CNS Drugs (2014)
Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease
Marie Therese Armentero;Annalisa Pinna;Sergi Ferré;José Luis Lanciego.
Pharmacology & Therapeutics (2011)
Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats.
Annalisa Pinna;Sandro Fenu;Micaela Morelli.
Adenosine A2 receptors interact negatively with dopamine D1 and D2 receptors in unilaterally 6-hydroxydopamine-lesioned rats
Micaela Morelli;Sandro Fenu;Annalisa Pinna;Gaetano Di Chiara.
European Journal of Pharmacology (1994)
Modification of adenosine extracellular levels and adenosine A2A receptor mRNA by dopamine denervation
Annalisa Pinna;Claudia Corsi;Anna Rosa Carta;Valentina Valentini.
European Journal of Pharmacology (2002)
Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6‐hydroxydopamine rat model of Parkinson's disease
Annalisa Pinna;Silvia Pontis;Franco Borsini;Micaela Morelli.
New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists.
Annalisa Pinna;Jadwiga Wardas;Nicola Simola;Micaela Morelli.
Life Sciences (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: